C23H20F3N5O2S2
Neat
519.57
-20°C
Room Temperature
Dabrafenib; 1195765-45-7; GSK2118436; GSK2118436A; GSK-2118436; QGP4HA4G1B; GSK-2118436A; Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2, 6-difluoro-; CHEBI:75045; DTXSID20152499; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide; BENZENESULFONAMIDE, N-(3-(5-(2-AMINO-4-PYRIMIDINYL)-2-(1, 1-DIMETHYLETHYL)-4-THIAZOLYL)-2-FLUOROPHENYL)-2, 6-DIFLUORO-; N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1, 3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2, 6-DIFLUOROBENZENESULFONAMIDE; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl}-2 and 6-difluorobenzenesulfonamide; dabrafenibum; RefChem:58040; DTXCID8074990; BRAF Inhibitor GSK2118436; L01XE23; 689-166-9
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2 and 6-difluorobenzenesulfonamide
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)